

1 *Acute and Subacute Ischemia of Lower Limbs: Angiography and Peripheral Hemodynamics.*
2 *Bulvas M, Sommerová Z.*
3

4

5 **Acute and Subacute Ischemia of Lower Limbs:** 6 **Angiography and Peripheral Hemodynamics**

7

8 Running title: Acute and subacute limb ischemia

9 Miroslav Bulvas, MD. PhD. Assoc. Prof.

10 Zuzana Sommerová, MD. PhD.

11

12 Affiliations:

13 Miroslav Bulvas, Department of Surgery, Division of Angiology, University Hospital

14 Královské Vinohrady, Third Faculty of Medicine, Charles University (address: Šrobárova 50,
15 100 34, Prague 10, Czech Republic)

16

17 Zuzana Sommerová, Center for Cardiovascular Prevention, First Faculty of Medicine and

18 Thomayer Hospital, Charles University (address: Vídeňská 800, 140 59 Prague 4, Czech

19 Republic), email: zuzanasommerova@mybox.cz

20

21

22 Corresponding author: Miroslav Bulvas, email: bulvasm@seznam.cz

23

24

miroslav.bulvas@lf3.cuni.cz

25

phone: +420 603426473

26

address: U Michelského mlýna 35, 140 00 Prague 4,
27 Czech Republic

28

ORCID iD: 0000-0003-4211-6696

29

30 Acknowledgments

31 The authors thank Candance McClure (NAMSA, Toledo, OH, USA) and Marian
32 Rybář (MATSTAT, Prague, Czech Republic) for statistical expertise.

33

34 Declaration of Conflicting Interests: The authors have no potential conflicts of interest with
35 respect to the research, authorship, and/or publication of this article.

36

37 Funding

38 The authors received no financial support for the research, authorship, and/or
39 publication of this article.

40

41

42

43

44 **ABSTRACT**

45

46 **Objective:** To identify pretreatment characteristics related to ischemia severity and symptoms
47 duration in patients with acute (ALI) and subacute lower limb ischemia (SLI).

48 **Methods:** Comparative study, a part of prospective, single-arm, single-center trial of 316
49 consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years,
50 range: 23-96; 184 men) of whom 99.4 % suffered from acute or subacute supratibial
51 occlusions (target occlusions).

52 **Results:** Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented
53 in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The
54 value of ABI related to the number of occluded tibial arteries. Occlusion locations associated
55 with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI
56 subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number
57 of patent tibial arteries and lower ABI.

58 **Conclusion:**

59 Anatomically, the most important factor related to the ischemia severity and symptoms
60 duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or
61 chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to
62 ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb
63 and should be always considered.

64

65

66

67

68

69

70

71 INTRODUCTION

72 Acute lower limb ischemia (ALI) is a critical vascular emergency that endangers the
73 affected extremity and puts the patient's life at risk. It is defined as a sudden decrease in or
74 worsening of limb perfusion that has been present for 14 days or less and causing a potential
75 threat to limb viability^{1,2}.

76 The clinical presentation of ALI is not single and varies from viable to irreversibly
77 damaged extremity. The limb can be threatened immediately after the symptoms origin or
78 later when ischemia progresses, steadily or in steps. The fact that suddenly developed
79 ischemia can escalate during the time period longer than 2 weeks, led many authors to use
80 the term "subacute limb ischemia" (SLI) to distinguish the unstable and developing condition
81 from the chronic, stable ischemic status. The guidelines^{3,4} defined SLI by symptoms duration
82 longer than 14 days, and lasting up to 3 months.

83 The pre-treatment factors, reported in the literature^{5,6} to influence the mortality and
84 amputation rates were high age, female gender, non-Caucasian race, comorbidities (diabetes,
85 malignancy, neurological disorders, coronary heart disease, congestive heart disease),
86 multilevel occlusion, more proximal occlusions, limb ischaemia severity, treatment risk and
87 urgency, tissue damage, repeated ALI attacks, absence of early anticoagulation and delay in
88 diagnosis and revascularization. However, their role and incidence may differ in patients with
89 different clinical presentation.

90 Because the same initial treatment techniques (open surgery, catheter-directed
91 thrombolysis, mechanical thrombectomy) are used in patients with ALI or SLI⁷, different
92 number of patients with SLI and those with ALI categorized as type I (viable extremity), IIA
93 (marginally threatened) or IIB (immediately threatened) have been often grouped in ALI
94 cohorts in studies to date analyzing surgical and/or endovascular treatment outcomes. To
95 understand whether such a grouping can affect the overall results and comparability among
96 the studies, it is important to learn more about characteristic of individual clinical categories.

97 Closer knowledge is necessary for better understanding the high mortality and amputation
98 rates, and the factors associated with or responsible for clinical presentation, serious events
99 and technical failure of therapeutic intervention.

100 The aim of this study was to identify the relations of ischemia severity and/or
101 symptoms duration with age, gender, comorbidities, clinical presentation, arterial occlusion
102 aetiology, vascular anatomy and peripheral hemodynamics in patients with threatened lower
103 extremity due to ALI (IIA, IIB) or SLI. Specifically, we focused on the role of infrapopliteal
104 arterial patency in 316 patients (all-comers) of whom 99.4 % primarily suffered from acute
105 or subacute supratibial occlusions (target occlusions).

106 MATERIAL AND METHODS

107 Our study was a single-centre, prospective, single-arm trial performed during the time
108 interval 2009–2015 with two main goals. The first part documented the efficacy, safety and
109 applicability of endovascular removal of occlusive material as the initial treatment in patients
110 with limb threatening ALI and SLI. It was already published⁸.

111 In this report, we focused on pre-treatment difference between clinical categories (ALI
112 vs. SLI, ALI IIB vs. ALI IIA, females vs. males, thrombotic occlusion vs. embolism). We
113 compared demographic data, frequencies of risk factors and comorbidities, clinical data,
114 ankle-brachial pressure index (ABI) and vascular anatomy characteristics (Table 1, 2).

115 The target lesion and vascular anatomy information was obtained by digital
116 subtraction angiography in all patients. No therapeutic interventions were performed or tested
117 in this part of the study.

118 The study included 316 consecutive patients (all-comers, 184 men, mean age: $70.9 \pm$
119 12.0 years): 202 subjects with ALI (114 men, mean age: 72.6 ± 12.2 , mean symptoms
120 duration: 4.13 ± 4.47 days; 146 patients categorized as IIB of the Rutherford classification for
121 acute limb ischaemia²; 56 patients of the category IIA) and 114 patients with SLI (70 men,

122 mean age: 67.9 ± 10.9 years; mean symptoms duration: 44.3 ± 27.3 days). SLI patients were
123 categorized on the basis of the Rutherford classification for chronic limb ischemia ² (38
124 patients: category 3; 50 patients: category 4; 26 patients: category 5). Critical limb ischemia
125 was diagnosed in 74 patients with SLI according to established guidelines ^{1,9,10}.

126 Target, supratibial occlusions (acute or subacute) were located in aortoiliac arterial
127 segment, femoropopliteal segment, deep femoral artery, bypasses (aortofemoral,
128 femoropopliteal, femorofemoral) and leg of bifurcation stentgraft (Table 2) in 99.4 % of
129 patients. Isolated infrapopliteal occlusions were detected in two patients (0.6 %).

130 Occlusion cause was determined on the basis of clinical manifestation, angiographic
131 findings¹¹, resistance to guidewire penetration and occurrence of underlying lesion after the
132 clot removal. Thrombotic occlusion was diagnosed in 256 (81.0 %), and embolism in 60 (19.0
133 %) patients.

134 The University Hospital Královské Vinohrady and the Third Medical Faculty of the
135 Charles University Centralized Institutional Review Board approved the study protocol and
136 informed consent form (identifier: EK/IV-2/2009). The study was conducted in accordance
137 with Declaration of Helsinki, and all patients provided written informed consent. The trial was
138 registered with the International Standard Randomized Controlled Trials Number registry
139 (ISRCTN 154967770). The inclusion criteria allowed enrolment of adult patients with ALI
140 (symptoms duration ≤ 14 days) or SLI (symptoms duration >14 days and ≤ 3 months), severe
141 claudication, ischemic rest pain, sensorimotor deficit and/or tissue defects. Patients presented
142 from a variety of sources – overflow from other urban institutions, remote community
143 hospitals, physician referral, and self-presenting. The exclusion criteria were irreversible
144 ischemia and viable extremity.

145 Statistical analysis: continuous data are presented as the mean \pm standard deviation
146 (SD). Categorical data are given as the number (percentage). Continuous variables were

147 compared using a paired or unpaired t test or Wilcoxon rank sum test, as appropriate.
148 Categorical variables were analyzed using a 2 -sided chi-square or Fischer exact test, as
149 appropriate. For analysis of variance (ANOVA), Welch´s test for unequal sample sizes was
150 used. The threshold of statistical significance was $p < 0.05$. Statistical analyses were
151 performed using SAS software (version 9.4; SAS Institute, USA) and STATSOFT software
152 for Welch´s test (Statistica, version 10, USA).

153

154 RESULTS

155 *Anatomy*

156 The presence of acute or subacute supratibial arterial occlusions was documented in
157 314 (99.4 %) of 316 patients with threatened lower limbs due to ALI and SLI. Mean length
158 of supratibial occlusion was greater in group with ALI (244.6 mm) vs. SLI (202.0 mm),
159 $p=0.0159$ and in patients with thrombotic cause of the occlusion (246.6 mm) vs. embolism
160 (155.0 mm, $p<.0001$).

161 The most frequently occluded (acutely or subacutely) locations were the
162 femoropopliteal segment (in 73.1 % of 316 patients) and femoropopliteal bypass (22.8%).
163 Significant difference in frequency of femoropopliteal segment and femoropoplital bypass
164 occlusion was not documented between patients with ALI vs. SLI and ALI IIB vs. ALI IIA
165 (Table 1).

166 The aortoiliac segment occlusion was detected in 11.1 % of all patients, with higher
167 incidence in those with ALI (13.9 %) vs. SLI (6.1 %, $p=.0401$) (Table 2). The incidence of the
168 deep femoral artery occlusion was higher in patients with ALI vs. SLI (12.9 vs. 5.3 %, $p=0.0332$),
169 embolism vs. thrombosis (23.3 vs. 7.0 %, $p=.0006$) and females vs. males (15.2
170 vs. 6.5%, $p=.0142$) (Table 2).

171 Infrapopliteal occlusion (acute or subacute) additional to occlusion located
172 supratibially was documented in 61.7 % of all patients (ALI + SLI) with higher frequency in
173 patients with ALI (68.3 %) vs. SLI (50.0 %, $p=.0017$), ALI IIB (72.6 %) vs. ALI IIA (57.1 %, $p=.0427$) and embolism (73.3 %) vs. thrombosis (59.0 %, $p=.0403$) (Table 2, 4, 6).

175 Infrapopliteal occlusion (acute, subacute and chronic; segmental or total) in one, two
176 or three tibial vessels was detected in 86.1 % of 316 patients with significant difference
177 between ALI (90.6 %) vs. SLI (78.1 %, $p=.0036$) subjects. All tibial vessels occluded were
178 documented in 33.3 % of SLI and 62.4 % of ALI patients ($p=.0001$) (Fig. 1).

179 Higher mean number of patent (without acute, subacute or chronic occlusions) tibial
180 vessels was detected in patients with SLI (1.3) vs. ALI (0.7, $p<.0001$), ALI IIA (1.4) vs. ALI
181 IIB (0.4, $p<.0001$), thrombosis (1.0) vs. embolism (0.4, $p<.0001$) (Table 2, 4, 6).

182 Higher incidence of the femoropopliteal segment occlusion was established in subjects
183 with embolism (95.0 %) vs. thrombosis (68.0 %, $p<.0001$) and in female group (79.5 %) vs.
184 males (68.5 %, $p=.0296$).

185 Higher frequency of the femoropopliteal bypass occlusion was detected in the male
186 group (28.8 %) vs. females (14.4 %, $p=.0027$) and patients with thrombotic occlusion (27.7
187 %) vs. embolism (1.7 %, $p<.0001$) (Table 6, 7).

188

189 ***Ankle-brachial index***

190 Generally, the mean ABI was low (0.1) in the group of patients with ALI and SLI
191 before treatment. Its value was higher in patients with SLI (0.22) vs. those with ALI (0.08,
192 $p<.0001$), in subjects with ALI IIA (0.2) vs. ALI IIB (0.0, $p<.0001$) and in patients with
193 thrombosis (0.14) vs. embolism (0.07, $p=.0016$) (Table 2, 4, 6). In subgroup with ABI ranged
194 from 0.0 to 0.1, the patients with ALI were in majority (71.2 %). Patients with SLI dominated
195 in the subgroups with ABI value from 0.2-0.5 (Fig 2).

196 The value of ABI significantly correlated ($p<.001$) with the number of patent calf
197 vessels in subjects with ALI or SLI (Fig. 3,4).

198

199 ***Target occlusion origin: embolism vs. thrombosis***

200 Embolism as the cause of target supratibial occlusion was detected in 19 % of patients
201 with ALI+SLI. This cause was more frequent in patients with ALI (24.8 %) vs. SLI ((8.8 %, $p=.0005$), ALI IIB (28.8%) vs. ALI IIA (14.3 %, $p=.0442$) and in females (29.5 %) vs. males
202 (11.4 %, $p<.0001$) (Table 2, 3, 7).

204 In comparison with thrombotic lesions, the embolic occlusions were shorter in average
205 (155 vs. 246.6 mm, $p<.0001$) and they were localized more frequently in the femoropopliteal
206 segment (95.0 vs. 68.0 %, $p<.0001$) and/or the deep femoral artery (23.3 vs. 7.0 %, $p=.0006$)
207 (Table 6).

208 In patients with embolic supratibial closure, higher number (73.3 vs. 59.0 %, $p=.0403$)
209 of those with additional occlusions (acute, subacute, chronic; embolic or thrombotic) located
210 infrapopliteally was detected. Additionally, these subjects presented lower number of patent
211 calf vessels (0.4 vs. 1.0, $p<.0001$) and lower ABI (0.07 vs. 0.14, $p=.0016$).

212 Embolism was also associated with higher age (73.7 vs. 70.2 years, $p=.0054$), higher
213 incidence of female gender (65.0 % vs. 36.3 %, $p<.0001$), cardiac disease (61.7 vs. 37.5 %, $p=.0008$), arrhythmias (51.7 vs. 19.5 %, $p<.0001$), ALI (83.3 vs. 59.4 %, $p=.0005$) and ALI
214 IIB (84.0 vs. 68.4 %, $p=.0442$).

216 On the other hand, patients with thrombotic occlusion presented more frequent male
217 gender (63.7 vs. 35 %, $p<.0001$), positive smoking history (59.8 vs. 31.7 %, $p<.0001$), SLI
218 (40.6 vs. 16.7 %, $p=.0005$), ALI IIA (31.6 vs. 16 %, $p=.0442$), claudication (32.4 vs. 15 %, $p=.0071$), critical limb ischaemia (26.6 vs.10 %, $p=.0062$), tissue defect (17.2 vs. 5 %, $p=.0151$), in-stent occlusion (27.7 vs. 5 %, $p<.0001$), femoropopliteal bypass occlusion (27.1

221 vs. 1.7 %, $p<.0001$) higher number of patent calf vessels (1.0 vs. 0.4, $p<.0001$) and higher
222 ABI (0.14 vs. 0.07, $p=.0016$) (Table 5,6).

223

224 ***Risk factors and concomitant disease***

225 Comparison between patients with SLI and ALI detected significantly higher
226 frequency of the smoking history (64.0 vs. 49.0 %, $p=.0134$), claudication (53.5 vs. 15.3 %, $p<.0001$) and tissue defect (22.8 vs.10.4 %, $p=.0047$). The ALI patients were older (mean age:
228 72.6 vs. 67.9 years, $p=.0005$), with longer target lesion (mean length: 244.6 vs. 202.0 mm, $p=.0159$), higher frequency of rest pain (83.7 vs. 57.9 %, $p<.0001$), embolism (24.8 vs. 8.8 %, $p=.0005$), arrhythmias (30.7 vs. 16.7 %, $p=.0071$). A higher statistical trend toward increased
231 incidence of cardiac disease (46.0 vs. 35.1 %, $p=.0749$), cerebrovascular disease (28.2 vs.19.3
232 %, $p=.0809$) and renal insufficiency (26.7 vs. 17.5 %, $p=.0726$) was detected in ALI subjects
233 (Table 1,2).

234 Comparison between ALI patients with immediately (IIB) and marginally (IIA)
235 threatened extremities detected significantly higher frequency of diabetes (36.3 vs. 21.4 %, $p=.0452$), rest pain (91.8 vs. 62.5 %, $p<.0001$), embolism (28.8 vs. 14.3 %, $p=.0442$) in II B
237 subjects, together with lower mean number of patent calf vessels (0.4 ± 0.9 vs. 1.4 ± 1.1 , $p<.0001$), ankle-brachial index (0.0 ± 0.1 vs. 0.2 ± 0.2 , $p<.0001$) and shorter mean duration of
239 the ischaemic symptoms (3.1 vs. 6.8 days, $p=.0004$). Patients with ALI IIB also presented
240 higher incidence of the cerebrovascular disease (32.2 vs. 17.9 %, $p=.0543$) and the renal
241 insufficiency (26.7 vs. 17.5 %, $p=.0726$), but those differences were beyond the statistical
242 significance (Table 3,4).

243 Subjects with ALI IIA presented higher frequency of smoking history (60.7 vs. 44.5
244 %, $p=.0425$), hyperlipidaemia (50.0 vs. 32.9 %, $p=.0344$), claudication (39.3 vs. 6.2 %, $p=.0344$),

245 p<.0001) and thrombosis (85.7 vs. 71.2 %, p=.0442+) as the cause of target occlusion (Table
246 3, 4).

247

248 ***Gender: Females vs. males***

249 Female gender was associated with higher mean age (75.1 vs. 67.9 years, p<.0001),
250 higher incidence of hypertension (81.1 vs. 70.1 %, p=.0355), arrhythmias (34.8 vs. 19.0 %,
251 p=.0017) and embolism (29.5 vs. 11.4 %, p<.0001) as the cause of target arterial occlusion.
252 Additionally, the occlusion was more frequently located in the femoropopliteal arterial
253 segment (79.5 vs. 68.5 %, p=.0296) and the deep femoral artery (15.2 vs. 6.5 %, p=.0142) in
254 this subgroup. Male subgroup presented more frequent smoking history (67.4 vs. 36.4 %,
255 p<.0001), renal insufficiency (27.7 vs. 17.4 %, p=.0429), tissue defect (18.5 vs. 9.8 %,
256 p=.0375), thrombotic cause of the occlusion (88.6 vs. 70.5 %, p<.0001) and femoropopliteal
257 bypass occlusion (28.8 vs. 14.4 %, p=.0027). A higher statistical trend in favour of
258 claudication (33.2 vs. 23.5 %, p=.0785) was also detected in this subgroup (Table 7).

259

260 ***Clinical presentation***

261 Comparison between ALI patients with immediately (IIB) and marginally (IIA)
262 threatened extremities detected significantly shorter mean duration of the ischaemic
263 symptoms (3.1 vs. 6.8 days, p=.0004). The incidence of tissue defects was higher in males
264 (18.5 % vs. 9.8 %, p=.0375), SLI vs. ALI (22.8 vs 10.4 %, p=.0047), patients with
265 thrombosis vs. embolism (17.2 vs. 5.0 %, p=.0151). The rest pain occurred more frequently
266 in ALI group (83.7 % vs. 57.9 %, p<.0001), and in ALI IIB vs. ALI IIA (91.8 vs. 62.5 %,
267 p<.0001). The claudication was detected in 53.5 % of subjects with SLI (vs. 15.3 % in ALI,
268 p<.0001), 39.3 % of ALI IIA (vs. 6.2 % in ALI IIB, p<.0001) and in patients with thrombosis
269 (32.4 %) vs. embolism (15.0 %, p=.0071) (Table 1,3,5,7).

270 DISCUSSION

271 Ischaemia severity, symptoms duration and their progression in time vary with the
272 grade and dynamics of blood flow deterioration. Vessel anatomy before ALI attack, site and
273 cause of acute arterial occlusion, collateral development, embolus fragmentation and its
274 displacement to the peripheral branches, thrombosis progression, runoff quality and
275 antithrombotic therapy are the factors influencing clinical presentation of ALI. Together with
276 serious comorbidities, they affect periprocedural, early and long-term treatment outcomes,
277 morbidity, mortality and amputation rates. Detailed angiography description and pre-
278 treatment ABI data were often not presented in the study reports dedicated to surgical and/or
279 endovascular therapy of ALI. Thus, the correlation of ischaemic symptoms and their duration
280 with the limb hemodynamics and vascular anatomy is difficult or impossible from the
281 literature.

282 In retrospective analysis of 160 ALI patients (symptoms duration 7 days or less, 13 %
283 embolic and 87 % thrombotic occlusions, 75 % clinical category II) managed with 186
284 intraarterial thrombolytic procedures, McNamara and colleagues¹² correlated angiographic
285 patterns with clinical severity of ischemia. They based the angiographic categorization on the
286 number of occluded arterial segments (common iliac, external iliac, common femoral,
287 superficial femoral, popliteal, trifurcation, bypass grafts), presence of visible patent distal
288 vessels, existence of patent collateral vessels, and the occurrence of stenoses involving inflow,
289 collateral, or outflow vessels. Clinical category “viable“ (I) correlated with single-segment
290 occlusion, patent collaterals and distal vessels. Patients requiring blood to flow through two
291 contiguous collateral beds to supply distal vessels or with single occlusion combined with
292 stenosis of the adjacent inflow, outflow or collateral vessel correlated with the clinical
293 category “threatened“ (II). Occlusions of more than two segments with distal propagation that
294 occluded the distal vascular bed correlated with the clinical category “irreversible“ (III).

295 Severity of ischemia and extent of the occlusion correlated with death and amputation rate at
296 30 days.

297 In their study of 45 patients with embolic occlusions managed by thrombolysis, Huettl
298 and Soulen¹³ detected no patent calf vessels in 56 % of patients, one calf vessel was patent in
299 22 %, two in 7 % and three in 16 % of patients before treatment. Those numbers are close to
300 our data. Using thrombolysis and additional endovascular techniques for treatment of non-
301 embolic ALI in 119 patients (72 % grafts, 68 % category I), Kashyap and associates¹⁴
302 detected multisegmental thrombosis in 16 % and tibial thrombosis in 22 % of patients. Distal
303 occlusions beyond the reach of the rheolytic catheter limited the treatment in 57 % of 86
304 patients with ALI or SLI in the study of Kasirajan et al¹⁵. The need for distal thrombectomy
305 and poor intra-operative runoff were detected among risk factors for amputation and death in
306 107 patients with ALI undergoing infrainguinal bypass¹⁶. Also, any patent pedal outflow was
307 a significant predictor for technical success in patients with ALI managed surgically (296 pts)
308 or by endovascular technique (147 pts) in the study of Taha and associates¹⁷. Failed
309 mechanical recanalization of the diffusely occluded infrapopliteal vascular bed influenced the
310 need for thrombolytic therapy, the rate of major bleeding, treatment outcomes, amputation
311 and mortality rates in patients with ALI and SLI⁸.

312 The greatest mean lesion lengths were reported in the studies of ALI and SLI patients
313 with target occlusions located in the femoropopliteal bypass (32.1; 28.4 cm)^{18,19}. In our series,
314 the mean length of the target occlusion was 22.9 cm and 22.8 % of 316 patients suffered from
315 occluded femoropopliteal bypass.

316 The comparison between patients with embolic vs. thrombotic cause of arterial
317 occlusions, we documented higher age, higher frequency of female gender, cardiac disease,
318 arrhythmias, ALI, ALI IIB, occlusions of femoropopliteal segment and/or profunda femoris in
319 subjects with embolism. They also presented higher frequency of additional infrapopliteal

320 occlusion, lower number of patent tibial vessels and lower ABI before treatment. Thus,
321 historical view that embolism produces more severe ischaemia than thrombosis was
322 confirmed.

323 Thrombosis subgroup presented higher incidence of male gender, smoking history,
324 subacute ischemia, acute ischemia IIA, claudication, tissue defect, femoropopliteal bypass and
325 in-stent occlusions. Furthermore, these patients presented greater mean occlusion length,
326 higher ABI and number of patent calf vessels. Aune and Trippestad²⁰ reported in their study
327 of 272 patients managed by embolectomy (192 pts. with embolism) or bypass (80 pts. with
328 thrombosis), a higher mean age, frequency of female gender and cardiac disease, together
329 with shorter life expectancy in patients with embolism. Kuukasjarvi et al. in their study of 509
330 ALI patients (without previous reconstructions) from National Vascular Registry²¹ detected
331 higher frequency of embolism in patients of age 75 or more years and smoking as a risk factor
332 for acute thrombosis. The authors speculated that the worse prognosis (higher amputation
333 rate, mortality rates and necessity for repeated interventions) of patients with acute thrombotic
334 occlusion was associated with advanced atherosclerosis.

335 Higher age and frequency of hypertension, arrhythmias, embolism, occlusions of
336 femoropopliteal segment and deep femoral artery were associated with female gender.
337 Smoking history, renal insufficiency, tissue defects, thrombosis as a cause of the occlusion
338 and femoropopliteal bypass occlusion were more frequent in patients of male gender.
339 Additionally, we observed statistical trend toward more frequent claudication in the male
340 group.

341 Similar results can be found in the literature. Braithwaite and colleagues²² managed
342 84 elderly patients (75-100 years) with ALI by surgery and/or thrombolysis. Percentage of
343 females was 71.4 % in their series and female preponderance was greatest (84.8 %) in the
344 subgroup selected for immediate embolectomy. Female predominance was detected also in

345 other studies: 57 % in subgroup with embolism¹⁸ and 54 % of 23 268 ALI patients of the
346 National Inpatient Sample (NIS)²³. Kashyap and associates¹⁴ reported increased risk of limb
347 loss with the female gender in 119 ALI patients managed by thrombolysis. Mortality rate was
348 6 % and dying patients were women only. Female gender as a risk associated with limb
349 amputation was detected also by Kuoppala M and colleagues²⁴. The NATALI study²⁵
350 described female gender as a risk factor for mortality and for all and major complications
351 associated with thrombolytic treatment. On the other hand, Eliason JL et al.²³ reported
352 decreased risk of amputation in women, in patients with embolectomy, percutaneous
353 transluminal angioplasty and age less than 63 years in NIS patients. The authors did not detect
354 the female preponderance or lower amputation risk in their single institution study (105
355 patients).

356 ***CONCLUSION:***

357 Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented
358 in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The
359 value of ABI related to the number of occluded tibial arteries.

360 The most frequent locations of supratibial occlusions were femoropopliteal segment
361 (73.1 %) and femoropopliteal bypass (22.8 %) without significant difference in clinical
362 categories. Occlusion locations related to ALI (IIA+IIB) were the aortoiliac segment and/or
363 profunda femoris. Also, more ALI subjects presented additional infrapopliteal occlusion
364 (acute and/or subacute) and lower number of patent tibial arteries and lower ABI.

365 Anatomically, the important factor related to the ischaemia severity and symptoms
366 duration was the status of infrapopliteal vascular bed. The number of patent or acutely,
367 subacutely and chronically occluded tibial vessels related to individual clinical categories of
368 ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage
369 of threatened limb and should be always considered.

370 Patients with the most severe ischaemia and immediately threatened extremity (ALI
371 IIB) presented shortest symptoms duration, higher frequency of rest pain, embolism, diabetes,
372 additional acute infrapopliteal occlusion, lower number of patent tibial vessels and lower ABI
373 in comparison with ALI IIA patients. More frequent diabetes can participate on higher
374 number of occluded tibial vessels in this subgroup.

375 On the other hand, more patients with thrombosis, smoking history, hyperlipidemia,
376 claudication, higher number of patent calf vessels and higher ABI were detected in ALI IIA
377 subgroup.

378 In comparison with ALI group, the subjects with SLI presented more frequently the
379 thrombosis as a cause of target occlusion, smoking history, claudication, tissue defects,
380 shorter target occlusion, lower number of occluded tibial vessels and higher ABI.
381 Furthermore, they presented younger age, less embolism and arrhythmias, less aortoiliac
382 segment and deep femoral artery occlusions.

383 Embolism as a cause of the supratibial arterial occlusion was associated with higher
384 age, female gender, cardiac disease, arrhythmias, ALI, ALI IIB, femoropopliteal segment and
385 deep femoral artery occlusions, infrapopliteal occlusions, lower ABI and number of patent
386 calf vessels. Higher ischaemia severity in subjects with embolism was not associated only
387 with the fact that embolus suddenly occluded healthy supratibial artery but also with higher
388 frequency of additional infrapopliteal occlusion, profunda femoris occlusion and the higher
389 number of occluded tibial vessels. The data confirmed a historical view that the most severe
390 ischemia occurs with the embolism.

391 Thrombosis was associated with smoking history, SLI, ALI IIA, claudication, tissue
392 defects, longer target lesion, femoropopliteal bypass occlusion, in-stent occlusion, higher ABI
393 and number of patent calf vessels.

394 Patients of female gender presented higher age, higher frequency of hypertension,
395 arrhythmias, embolism, femoropopliteal and profunda femoris occlusions. Male group
396 manifested a higher frequency of smoking history, renal insufficiency, tissue defect,
397 thrombosis and femoropopliteal bypass occlusion.

398 Grouping the patients categorized in different clinical categories of ALI and SLI can
399 affect the treatment outcomes.

400


401 REFERENCES

- 402 1. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of
403 peripheral arterial diseases (TASC II). *Eur J Vasc Endovasc Surg* 2007;33, suppl 1:S1-S75.
- 404 2. Rutherford RB, Baker JD, Ernst C et al. Recommended standards for reports dealing with
405 lower extremity ischemia: Revised version. *J Vasc Surg* 1997;26:517-538.
- 406 3. Patel N, Sacks D, Patel RI et al. SCVIR reporting standards for the treatment of acute limb
407 ischemia with use of transluminal removal of arterial thrombus. *J Vasc Interv Radiol*
408 2001;12:559-570.
- 409 4. Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for
410 percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for
411 acute lower-limb ischemia. *Cardiovasc Intervent Radiol* 2011;34:1123-1136.
- 412 5. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. *Surgery*
413 1998;124:336-342.
- 414 6. Henke PK. Contemporary management of acute limb ischemia: factors associated with
415 amputation and in-hospital mortality. *Semin Vasc Surg* 2009;22:34-40.
- 416 7. Dosluoglu HH, Harris LM. Endovascular management of subacute lower extremity
417 ischemia. *Semin Vasc Surg* 2008;21:167-179.
- 418 8. Bulvas M, Sommerová Z, Vaněk I, Weiss J. Prospective single-arm trial of endovascular
419 mechanical debulking as initial therapy in patients with acute and subacute lower limb
420 ischemia: one-year outcomes. *J Endovasc Ther* 2019;26:291-301.
- 421 9. Hirsch AT, Haskal ZJ, Hertzler NR, et al. ACC/AHA 2005 guidelines for the management
422 of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal
423 aortic): executive summary. A collaborative report from the American Association for
424 Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and
425 Interventions, Society for Vascular Medicine and Biology, Society of Interventional
426 Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to
427 Develop Guidelines for the Management of Patients With Peripheral Arterial Disease).
428 Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;
429 National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-
430 Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol* 2006;47:1239-
431 1312.

432

- 433 10. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and
434 treatment of peripheral artery diseases: document covering atherosclerotic disease of
435 extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The
436 Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European
437 Society of Cardiology (ESC). *Eur Heart J* 2011;32:2851–2906.
438
- 439 11. O’Connell JB, Quiñones-Baldrich WJ. Proper evaluation and management of acute
440 embolic versus thrombotic limb ischemia. *Semin Vasc Surg* 2009;22:10-16.
- 441 12. McNamara TO, Gardner KR, Bomberger RA, Greaser LE. Clinical and angiographic
442 selection factors for thrombolysis as initial therapy for acute lower limb ischemia. *J Vasc*
443 *Interv Radiol* 1995;6(suppl):36S-47S.
444
- 445 13. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of
446 the results of the Star Registry. *Radiology* 1995;197:141-145.
447
- 448 14. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovascular therapy for
449 acute limb ischemia. *J Vasc Surg* 2011;53:340-46.
450
- 451 15. Kasirajan K, Gray B, Beavers FP, Clair DG, Greenberg R, Mascha E, Ouriel K. Rheolytic
452 thrombectomy in the management of acute and subacute limb-threatening ischemia.
453 *J Vasc Interv Radiol* 2001; 12:413–421.
454
- 455 16. Marqués de Marino P, Martínez López I, Revuelta Suero S et al. Results of infrainguinal
456 bypass in acute limb ischaemia. *Eur J Vasc Endovasc Surg* 2016;51:824-30.
457
- 458 17. Taha AG, Byrne RM, Avgerinos ED, Marone LK et al. Comparative effectiveness of
459 endovascular versus surgical revascularization for acute lower extremity ischemia *J Vasc Surg*
460 2015;61:147-54.
461
- 462 18. Hundt W, Kalinowski M, Stamm AC, Portig I, Swaid Z, Dietz C, Geks J, Burbelko M.
463 Combined treatment of subacute and acute synthetic and venous bypass-graft occlusions with
464 percutaneous mechanical thrombectomy and thrombolysis. *Eur J Radiol* 2013;82:e807– e815.
465 doi: 10.1016/j.ejrad.2013.08.016
- 466 19. Wissgott C, Kamusella P, Andresen R. Recanalization of acute and subacute venous and
467 synthetic bypass-graft occlusions with a mechanical rotational catheter. *Cardiovasc Intervent*
468 *Radiol* 2013;36:936–942.
469
- 470 20. Aune S, Trippstad A. Operative mortality and long-term survival of patients operated on
471 for acute lower limb ischaemia. *Eur J Vasc Endovasc Surg* 1998;15:143-146.
472
- 473 21. Kuukasjarvi P, Salenius J.P and the Finnvasc study group. Perioperative outcome of acute
474 lower limb ischaemia on the basis of the National Vascular Registry. *Eur J Vasc Surg*
475 1994;8:578-583.
476
- 477 22. Braithwaite BD, Davies B, Birch PA, Heather BP, Earnshaw JJ. Management of acute leg
478 ischaemia in the elderly. *Brit J Surg* 1998;85:217-220.
479


- 480 23. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA et al. A National and single
481 institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann
482 Surg 2003;238:382-390.
- 483 24. Kuoppala M, Franzén S, Lindblad B, Acosta S. Long-term prognostic factors after
484 thrombolysis for lower limb ischemia. J Vasc Surg 2008;47:1243-1250.
- 485
486 25. Earnshaw JJ, Whitman B, Foy C for the Thrombolysis Study Group. National Audit of
487 Thrombolysis for Acute Leg Ischemia (NATALI): Clinical factors associated with early
488 outcome. J Vasc Surg 2004;39:1018-25.
489



Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Number of patent calf vessels before treatment	n Mean ± SD	316 0.9 ± 1.1	114 1.3 ± 1.2	202 0.7 ± 1.0	<.0001
Patients with no patent tibial vessels	% (n/N)	51.9% (164/316)	33.3% (38/114)	62.4% (126/202)	0.0001
Patients with 1 patent tibial vessel	% (n/N)	17.7% (56/316)	22.8% (26/114)	14.9% (30/202)	0.0914
Patients with 2 patent tibial vessels	% (n/N)	16.5% (52/316)	21.9% (25/114)	13.4% (27/202)	0.0581
Patients with 3 patent tibial vessels	% (n/N)	13.9% (44/316)	21.9% (25/114)	9.4% (19/202)	0.0036


Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

ABI in Subacute and Acute Ischemia




Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
ABI before treatment	n Mean ± SD	309 0.1 ± 0.2	108 0.2 ± 0.2	201 0.1 ± 0.1	<.0001
ABI 0-0.1	% (n/N)	57% (176/309)	31.4% (34/108)	71.2% (143/201)	<.0001
ABI 0.11-0.2	% (n/N)	8.7% (27/309)	7.6% (8/108)	9.0% (18/201)	0.8302
ABI 0.21-0.3	% (n/N)	14.2% (44/309)	25.7% (28/108)	8.5% (17/201)	0.0001
ABI 0.31-0.4	% (n/N)	13.9% (43/309)	23.8% (26/108)	8.0% (16/201)	0.0002
ABI 0.41-0.5	% (n/N)	4.5% (14/309)	8.6% (9/108)	2.5% (5/201)	0.0236
ABI 0.51-0.6	% (n/N)	1.3% (4/309)	2.8% (3/108)	0.5% (1/201)	0.1245
ABI 0.61-0.7	% (n/N)	0.3% (1/309)	0% (0/108)	0.5% (1/201)	

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)					
Welch ANOVA test (p<0.001)					
SLI tibial vessels patent	ABI SLI Means	ABI SLI N	ABI SLI SD	ABI SLI Minimum	ABI SLI Maximum
0	0.139	37	0.160	0	0.420
1	0.214	21	0.129	0	0.450
2	0.244	25	0.156	0	0.460
3	0.346	24	0.150	0	0.600
All Groups	0.229	107	0.168	0	0.600

Fig. 3. The number of patent tibial vessels significantly ($p<.001$) correlates to ABI in SLI patients .



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)					
Welch ANOVA test (p<0.001)					
ALI tibial vessels patent	ABI ALI Means	ABI ALI N	ABI ALI SD	ABI ALI Minimum	ABI ALI Maximum
0	0.032	125	0.090	0	0.460
1	0.150	30	0.165	0	0.460
2	0.151	27	0.173	0	0.560
3	0.149	19	0.176	0	0.620
All Groups	0.081	201	0.140	0	0.620

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly ($p<0.001$) correlates to ABI.

LEGENDS

Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 – 0.5), SLI is more frequent.

Fig. 3. The number of patent tibial vessels significantly ($p<.001$) correlates to ABI in SLI patients.

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly ($p<.001$) correlates to ABI.

Table 1. Demography, concomitant disease, ischemia classification and symptoms: SLI vs. ALI

Table 2. Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Table 5. Demographics, concomitant disease, ischemia classification and symptoms: thrombosis vs. embolism

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Table 7. Age, concomitant disease, symptoms, ischemia classification, occlusion length and location: female vs. male gender

Table 1. Demography, concomitant disease, ischaemia classification and symptoms: SLI vs.

ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Age (years)	n Mean ± SD Median Range	316 70.9 ± 12.0 71.0 23.0, 96.0	114 67.9 ± 10.9 67.0 31.0, 94.0	202 72.6 ± 12.2 73.0 23.0, 96.0	0.0005
Male	% (n/N)	58.2% (184/316)	61.4% (70/114)	56.4% (114/202)	0.4079
Diabetes	% (n/N)	30.7% (97/316)	28.1% (32/114)	32.2% (65/202)	0.5256
Smoking history	% (n/N)	54.4% (172/316)	64.0% (73/114)	49.0% (99/202)	0.0134
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.2% (47/114)	37.6% (76/202)	0.5496
Hypertension	% (n/N)	74.7% (236/316)	73.7% (84/114)	75.2% (152/202)	0.7884
Cardiac disease	% (n/N)	42.1% (133/316)	35.1% (40/114)	46.0% (93/202)	0.0749
Arrhythmias	% (n/N)	25.6% (81/316)	16.7% (19/114)	30.7% (62/202)	0.0071
Cerebrovascular disease	% (n/N)	25.0% (79/316)	19.3% (22/114)	28.2% (57/202)	0.0809
Malignant disease	% (n/N)	7.3% (23/316)	7.9% (9/114)	6.9% (14/202)	0.8226
Renal insufficiency	% (n/N)	23.4 % (74/316)	17.5 % (20/114)	26.7 % (54/202)	0.0726
Acute limb ischaemia category IIA	% (n/N)	17.7% (56/316)		27.7% (56/202)	
Acute limb ischaemia category IIB	% (n/N)	46.2% (146/316)		72.3% (146/202)	
Subacute limb ischaemia	% (n/N)	36.1% (114/316)	100% (114/114)		
Symptoms duration	days	70.9±12.0	44.3±27.3	4.13±4.47	<.0001
Claudication	% (n/N)	29.1% (92/316)	53.5% (61/114)	15.3% (31/202)	<.0001
Rest pain	% (n/N)	74.4% (235/316)	57.9% (66/114)	83.7% (169/202)	<.0001
Tissue defect	% (n/N)	14.9% (47/316)	22.8% (26/114)	10.4% (21/202)	0.0047

Table 2 Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Target occlusion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 15.0, 650.0	114 202.0 ± 136.7 150.0 15.0, 650.0	202 244.6 ± 152.4 200.0 20.0, 590.0	0.0159
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	8.8% (10/114)	24.8% (50/202)	0.0005
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	91.2% (104/114)	75.2% (152/202)	0.0005
Aortoiliac segment occlusion	% (n/N)	11.1% (35/316)	6.1% (7/114)	13.9% (28/202)	0.0401
Femoropopliteal segment occlusion	% (n/N)	73.1% (231/316)	78.9% (90/114)	69.8% (141/202)	0.0868
Femoropopliteal bypass occlusion	% (n/N)	22.8% (72/316)	17.5% (20/114)	25.7% (52/202)	0.1241
Femoro-femoral cross bypass occlusion	% (n/N)	0.6% (2/316)	0	1.0% (2/202)	0.5373
Leg of bifurcation stentgraft occlusion	% (n/N)	0.3% (1/316)	0	0.5% (1/202)	1.0000
Ileofemoral bypass occlusion	% (n/N)	0.3% (1/316)	0.9% (1/114)	0	0.3608
Deep femoral artery occlusion	% (n/N)	10.1% (32/316)	5.3% (6/114)	12.9% (26/202)	0.0332
In-stent occlusion	% (n/N)	23.4% (74/316)	21.9% (24/114)	24.3% (49/202)	0.6800
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	50.0% (57/114)	68.3% (138/202)	0.0017
Number of patent calf vessels before treatment	n Mean ± SD Median Range	316 0.9 ± 1.1 0.0 0.0, 4.0	114 1.3 ± 1.2 1.0 0.0, 3.0	202 0.7 ± 1.0 0.0 0.0, 4.0	<.0001
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	108 0.2 ± 0.2 0.3 0.0, 0.6	201 0.1 ± 0.1 0.0 0.0, 0.6	<.0001

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB.

Characteristics	Summary Statistics	All ALI Subjects	ALI IIA	ALI IIB	p-value
Age (years)	n	202	56	146	0.2113
	Mean ± SD	72.6 ± 12.2	70.8 ± 12.9	73.2 ± 11.9	
	Median	73.0	73.0	74.0	
	Range	23.0, 96.0	23.0, 96.0	43.0, 96.0	
Male	% (n/N)	56.4% (114/202)	62.5% (35/56)	54.1% (79/146)	0.4079
Diabetes	% (n/N)	32.2% (65/202)	21.4% (12/56)	36.3% (53/146)	0.0452
Smoking history	% (n/N)	49.0% (99/202)	60.7% (34/56)	44.5% (65/146)	0.0425
Hyperlipidaemia	% (n/N)	37.6% (76/202)	50.0% (28/56)	32.9% (48/146)	0.0344
Hypertension	% (n/N)	75.2% (152/202)	71.4% (40/56)	76.7% (112/146)	0.4685
Cardiac disease	% (n/N)	46.0% (93/202)	41.1% (23/56)	47.9% (70/146)	0.4319
Arrhythmias	% (n/N)	30.7% (62/202)	28.6% (16/56)	31.5% (46/146)	0.7357
Cerebrovascular disease	% (n/N)	28.2% (57/202)	17.9% (10/56)	32.2% (47/146)	0.0543
Malignant disease	% (n/N)	6.9% (14/202)	5.4% (3/56)	7.5% (11/146)	0.7615
Renal insufficiency	% (n/N)	23.4% (74/316)	17.5% (20/114)	26.7% (54/202)	0.0726
Symptoms duration (days)	n	202	56	146	0.0004
	Mean ± SD	4.1±4.5	6.8±5.3	3.1±3.6	
	Median	2.0	6.5	2.0	
	Range	0.04, 14.0	0.08, 14.0	0.04, 14.0	
Claudication	% (n/N)	15.3% (31/202)	39.3% (22/56)	6.2% (9/146)	<.0001
	% (n/N)				
Rest pain	% (n/N)	83.7% (169/202)	62.5% (35/56)	91.8% (134/146)	<.0001
Tissue defect	% (n/N)	10.4% (21/202)	10.7% (6/56)	10.3% (15/146)	1.000
Target occlusion cause: Embolism	% (n/N)	24.8% (50/202)	14.3% (8/56)	28.8% (42/146)	0.0442
Target occlusion cause: Thrombosis	% (n/N)	75.2% (152/202)	85.7% (48/56)	71.2% (104/146)	0.0442

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Characteristics	Summary Statistics	All Subjects	ALI IIA	ALI IIB	p-value
Target occlusion length (mm)	n	202	56	146	0.0938
	Mean ± SD	244.6 ± 152.4	215.5 ± 150.2	255.7 ± 152.3	
	Median Range	200.0 20.0, 590.0	150.0 20.0, 550.0	220.0 20.0, 590.0	
Aortoiliac segment occlusion	% (n/N)	13.9 % (28/202)	14.3 % (8/56)	13.7 % (20/146)	1.000
Femoropopliteal segment occlusion	% (n/N)	69.8% (141/202)	69.6% (39/56)	69.9% (102/146)	1.000
Femoropopliteal bypass	% (n/N)	25.7 % (52/202)	25.0 % (14/56)	26.0 % (38/146)	1.000
Leg of bifurcation stentgraft occlusion	% (n/N)	0.5% (1/202)	1.8% (1/56)	0.5% (1/202)	0.2772
Ileofemoral bypass occlusion	% (n/N)	25.7% (52/202)	25.0% (14/56)	26.0% (38/146)	1.000
Deep femoral artery occlusion	% (n/N)	12.9% (26/202)	5.4% (3/56)	15.8% (23/146)	0.0597
In-stent occlusion	% (n/N)	24.3% (49/202)	33.9% (19/56)	20.5% (30/146)	0.0657
Additional infrapopliteal occlusion	% (n/N)	68.3% (138/202)	57.1% (32/56)	72.6% (106/146)	0.0427
No. of patent calf vessels before treatment	n	202	56	146	<.0001
	Mean ± std	0.7± 1.0	1.4 ± 1.1	0.4± 0.9	
	Median Range	0.0 0.0, 4.0	1.0 0.0, 3.0	0.0 0.0, 4.0	
ABI before treatment	n	201	55	146	<.0001
	Mean ± SD	0.1 ± 0.1	0.2 ± 0.2	0.0 ± 0.1	
	Median Range	0.0 0.0, 0.6	0.2 0.0, 0.6	0.0 0.0, 0.4	

Table 5. Demographics, concomitant disease, ischaemia classification and symptoms: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Age (years)	n	316	256	60	0.0054
	Mean ± SD	70.9 ± 12.0	70.2 ± 11.3	73.7 ± 14.2	
	Median	71.0	70.0	76.0	
	Range	23.0, 96.0	43.0, 96.0	23.0, 94.0	
Male	% (n/N)	58.2% (184/316)	63.7% (163/256)	35.0% (21/60)	<.0001
Female	% (n/N)	41.8% (132/316)	36.3% (93/256)	65.0% (39/60)	<.0001
Diabetes	% (n/N)	30.7% (97/316)	30.1% (77/256)	33.3% (20/60)	0.6425
Smoking history	% (n/N)	54.4% (172/316)	59.8% (153/256)	31.7% (19/60)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	39.5% (101/256)	36.7% (22/60)	0.7692
Hypertension	% (n/N)	74.7% (236/316)	74.6% (191/256)	75.0% (45/60)	1.0000
Cardiac disease	% (n/N)	42.1% (133/316)	37.5% (96/256)	61.7% (37/60)	0.0008
Arrhythmias	% (n/N)	25.6% (81/316)	19.5% (50/256)	51.7% (31/60)	<.0001
Cerebrovascular disease	% (n/N)	25.0% (79/316)	26.6% (68/256)	18.3% (11/60)	0.2458
Malignant disease	% (n/N)	7.3% (23/316)	7.8% (20/256)	5.0% (3/60)	0.5874
Renal insufficiency	% (n/N)	23.4% (74/316)	23.8% (61/256)	21.7% (13/60)	0.8657
Subacute ischaemia	% (n/N)	36.1% (114/316)	40.6% (104/256)	16.7% (10/60)	0.0005
Acute ischaemia	% (n/N)	63.9% (202/316)	59.4% (152/256)	83.3% (50/60)	0.0005
Acute ischaemia class IIA	% (n/N)	27.7% (56/202)	31.6% (48/152)	16.0% (8/50)	0.0442
Acute ischaemia class IIB	% (n/N)	72.3% (146/202)	68.4% (104/152)	84.0% (42/50)	0.0442
Claudication	% (n/N)	29.1% (92/316)	32.4% (83/256)	15.0% (9/60)	0.0071
Critical limb ischemia	% (n/N)	23.4% (74/316)	26.6% (68/256)	10.0% (6/60)	0.0062
Rest pain	% (n/N)	74.4% (235/316)	73.8% (189/256)	76.7% (46/60)	0.7436
Tissue defect	% (n/N)	14.9% (47/316)	17.2% (44/256)	5.0% (3/60)	0.0151

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Target lesion length (mm)	n	316	256	60	<.0001
	Mean ± SD	229.2 ± 148.1	246.6 ± 150.4	155.0 ± 111.7	
	Median	200.0	220.0	125.0	
	Range	15.0, 650.0	15.0, 650.0	20.0, 480.0	
Aortoiliac segment	% (n/N)	11.1% (35/316)	10.2% (26/256)	15.0% (9/60)	0.3588
Femoropopl segment	% (n/N)	73.1% (231/316)	68.0% (174/256)	95.0% (57/60)	<.0001
Femoropopl bypass	% (n/N)	22.8% (72/316)	27.7% (71/256)	1.7% (1/60)	<.0001
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (2/256)		
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Ileofemoral bypass	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Deep femoral artery	% (n/N)	10.1% (32/316)	7.0% (18/256)	23.3% (14/60)	0.0006
In-stent occlusion	% (n/N)	23.4% (74/316)	27.7% (71/256)	5.0% (3/60)	<.0001
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	59.0% (151/256)	73.3% (44/60)	0.0403
No. of patent calf vessels before treatment	n	316	256	60	<.0001
	Mean ± SD	0.9 ± 1.1	1.0 ± 1.1	0.4 ± 0.9	
	Median	0.0	1.0	0.0	
	Range	0.0, 4.0	0.0, 3.0	0.0, 4.0	
ABI before treatment	n	309	250	59	0.0016
	Mean ± SD	0.1 ± 0.2	0.14 ± 0.17	0.07 ± 0.14	
	Median	0.0	0.0	0.0	
	Range	0.0, 0.6	0.0, 0.6	0.0, 0.5	

Table 7. Age, concomitant disease, symptoms, ischaemia classification, occlusion length and location: female vs. male gender

Characteristics	Summary Statistics	All Subjects	Female	Male	p-value
Age (years)	n	316	132	184	<.0001
	Mean ± SD	70.9 ± 12.0	75.1 ± 11.4	67.9 ± 11.5	
	Median	71.0	76.5	67.5	
	Range	23.0, 96.0	23.0, 96.0	31.0, 94.0	
Diabetes	% (n/N)	30.7% (97/316)	33.3% (44/132)	28.8% (53/184)	0.3903
Smoking history	% (n/N)	54.4% (172/316)	36.4% (48/132)	67.4% (124/184)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.7% (55/132)	37.0% (68/184)	0.4147
Hypertension	% (n/N)	74.7% (236/316)	81.1% (107/132)	70.1% (129/184)	0.0355
Cardiac disease	% (n/N)	42.1% (133/316)	42.4% (56/132)	41.8% (77/184)	1.0000
Arrhythmias	% (n/N)	25.6% (81/316)	34.8% (46/132)	19.0% (35/184)	0.0017
Cerebrovascular disease	% (n/N)	25.0% (79/316)	25.0% (33/132)	25.0% (46/184)	1.0000
Malignant disease	% (n/N)	7.3% (23/316)	6.8% (9/132)	7.6% (14/184)	0.8301
Renal insufficiency	% (n/N)	23.4% (74/316)	17.4% (23/132)	27.7% (51/184)	0.0429
Acute limb ischaemia category IIA	% (n/N)	27.7% (56/202)	23.9% (21/88)	30.7% (35/114)	0.3420
Acute limb ischaemia category IIB	% (n/N)	72.3% (146/202)	76.1% (67/88)	69.3% (79/114)	0.3420
Claudication	% (n/N)	29.1% (92/316)	23.5% (31/132)	33.2% (61/184)	0.0785
Critical limb ischaemia	% (n/N)	23.4% (74/316)	21.2% (28/132)	25.0% (46/184)	0.5011
Rest pain	% (n/N)	74.4% (235/316)	78.8% (104/132)	71.2% (131/184)	0.1509
Tissue defect	% (n/N)	14.9% (47/316)	9.8% (13/132)	18.5% (34/184)	0.0375
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	29.5% (39/132)	11.4% (21/184)	<.0001
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	70.5% (93/132)	88.6% (163/184)	<.0001
Target occlusion length (mm)	n	316	132	184	0.5290
	Mean ± SD	229.2 ± 148.1	221.0 ± 142.1	235.1 ± 152.5	
	Median	200.0	200.0	200.0	
	Range	15.0, 650.0	20.0, 590.0	15.0, 650.0	
Aortoiliac segment	% (n/N)	11.1% (35/316)	14.4% (19/132)	8.7% (16/184)	0.1453
Femoropopliteal segment	% (n/N)	73.1% (231/316)	79.5% (105/132)	68.5% (126/184)	0.0296
Femoropopliteal bypass	% (n/N)	22.8% (72/316)	14.4% (19/132)	28.8% (53/184)	0.0027
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (1/132)	0.5% (1/184)	1.0000
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Ileofemoral bypass	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Deep femoral artery	% (n/N)	10.1% (32/316)	15.2% (20/132)	6.5% (12/184)	0.0142
In-stent occlusion	% (n/N)	23.4% (74/316)	24.2% (32/132)	22.8% (42/184)	0.7888
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	62.9% (83/132)	60.9% (112/184)	0.7266
Number of patent calf vessels	n	316	132	184	0.6844
	Mean ± SD	0.9 ± 1.1	0.9 ± 1.1	1.0 ± 1.1	
	Median	0.0	0.0	0.0	
	Range	0.0, 3.0	0.0, 3.0	0.0, 3.0	
ABI before treatment	n	309	129	180	0.2715
	Mean ± SD	0.1 ± 0.2	0.12 ± 0.16	0.14 ± 0.17	
	Median	0.0	0.0	0.0	
	Range	0.0, 0.6	0.0, 0.6	0.0, 0.6	